Biodesix, Inc., a fully integrated molecular diagnostics company dedicated to personalizing medicine, recently announced that it has obtained the CE Mark for its VeriStrat® specimen collection and shipping kit, clearing the company to make VeriStrat results available to physicians in the European Union and other countries recognizing the CE Mark. VeriStrat is a non-invasive, blood-based protein diagnostic that predicts differential treatment outcomes between two types of therapies for second-line treatment of non-operable, advanced non-small cell lung cancer (NSCLC): chemotherapy or the targeted drug erlotinib (Tarceva®). Physicians use VeriStrat results, in combination with other clinicopathological factors, to guide therapy decisions for non-small cell lung cancer patients.
Boehringer Ingelheim and Duke Clinical Research Institute Form Collaborative Partnership to Study the Natural History of Idiopathic Pulmonary Fibrosis (IPF)
Boehringer Ingelheim Pharmaceuticals, Inc. and Duke Clinical Research Institute (DCRI) have formed a unique collaborative relationship to uncover insights into idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease.
Critical Diagnostics recently announced the launch of ST2online.com, a free online resource designed to deliver clinical and research information specific to ST2—a cardiac biomarker that, in over 100 clinical trials has shown to be the most prognostic biomarker for improving the management of heart failure.
Bladder cancer patients, survivors, and families faced with life-long surveillance of the highly recurring disease are finding reassurance in Cxbladder. This new, non-invasive, urine based bladder cancer detection test developed by Pacific Edge Ltd measures the expression of five genes that create a unique molecular signature for bladder cancer, alerting doctors to possible tumors. More accurate than many other urine-based cancer detection tests, Cxbladder can give patients and doctors added confidence in their diagnoses.